Mark J. Ratain to Dihydrouracil Dehydrogenase (NADP)
This is a "connection" page, showing publications Mark J. Ratain has written about Dihydrouracil Dehydrogenase (NADP).
Connection Strength
0.576
-
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006 Aug; 27(8):432-7.
Score: 0.278
-
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clin Cancer Res. 2002 May; 8(5):1314; author reply 1315-6.
Score: 0.052
-
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil. Cancer Chemother Pharmacol. 2002 May; 49(5):398-402.
Score: 0.051
-
Pharmacogenetics: a tool for individualizing antineoplastic therapy. Clin Pharmacokinet. 2000 Nov; 39(5):315-25.
Score: 0.047
-
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy. Cancer Invest. 1999; 17(7):494-506.
Score: 0.041
-
Pharmacogenetics and cancer chemotherapy. Eur J Cancer. 1998 Sep; 34(10):1493-9.
Score: 0.040
-
Pharmacogenetics in cancer etiology and chemotherapy. Clin Cancer Res. 1997 Jul; 3(7):1025-30.
Score: 0.037
-
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Clin Cancer Res. 1999 Feb; 5(2):291-8.
Score: 0.010
-
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998 Apr; 16(4):1450-7.
Score: 0.010
-
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer. J Natl Cancer Inst. 1997 Feb 19; 89(4):308-13.
Score: 0.009